ELLIPSES PHARMA LTD has a total of 17 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2009. It filed its patents most often in Australia, United States and United Kingdom. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ObsEva SA, CALISTOGA PHARMACEUTICALS INC and Pharmacylics LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 7 | |
#2 | United States | 4 | |
#3 | United Kingdom | 3 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Hong Kong | 1 | |
#6 | Hungary | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Macromolecular chemistry and polymers | |
#5 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Heterocyclic compounds | |
#5 | Macromolecular compounds compositions | |
#6 | Polysaccharides | |
#7 | Electrotherapy |
# | Name | Total Patents |
---|---|---|
#1 | Gill Jason | 5 |
#2 | Loadman Paul | 5 |
#3 | Ryan John | 4 |
#4 | Patterson Laurence | 4 |
#5 | Falconer Robert | 4 |
#6 | Bibby Michael | 4 |
#7 | Schluep Thomas | 3 |
#8 | Tellez Andres | 2 |
#9 | Friedman Paul | 2 |
#10 | Lazarus Douglas | 2 |
Publication | Filing date | Title |
---|---|---|
GB202003100D0 | Salts and polymorphic forms of compound a | |
GB202003108D0 | Pharmaceutical formulations | |
EP3548028A1 | Treatment of cancer | |
GB201521215D0 | Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site | |
AU2013205079A1 | Treatment of cancer | |
AU2010295646A1 | Treatment of cancer |